PDF herunterladen
CC BY 4.0 · World J Nucl Med 2018; 17(04): 241-248
DOI: 10.4103/wjnm.WJNM_71_17
Original Article

Comparison of hybrid 18F.fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1

Roy A. Raad
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Shailee Lala
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Jeffrey C. Allen
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
James Babb
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Carole Wind Mitchell
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Ana M. Franceschi
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Kaleb Yohay
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
,
Kent P. Friedman
1   Departments of Radiology and 1Pediatrics and Neurology, NYU School of Medicine, New York, NY 10016, USA
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Rapidly enlarging, painful plexiform neurofibromas (PN) in neurofibromatosis type 1 (NF1) patients are at higher risk for harboring a malignant peripheral nerve sheath tumor (MPNST). Fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has been used to support more invasive diagnostic and therapeutic interventions. However, PET/CT imparts an untoward radiation hazard to this population with tumor suppressor gene impairment. The use of FDG PET coupled with magnetic resonance imaging (MRI) rather than CT is a safer alternative but its relative diagnostic sensitivity requires verification. Ten patients (6 females, 4 males, mean age 27 years, range 8–54) with NF1 and progressive PN were accrued from our institutional NF Clinic. Indications for PET scanning included increasing pain and/or progressive disability associated with an enlarging PN on serial MRIs. Following a clinically indicated whole?body FDG PET/CT, a contemporaneous PET/MRI was obtained using residual FDG activity with an average time interval of 3-4 h FDG?avid lesions were assessed for both maximum standardized uptake value (SUVmax) from PET/CT and SUVmax from PET/MR and correlation was made between the two parameters. 26 FDG avid lesions were detected on both PET/CT and PET/MR with an accuracy of 100%. SUVmax values ranged from 1.4–10.8 for PET/CT and from 0.2?5.9 for PET/MRI. SUVmax values from both modalities demonstrated positive correlation (r = 0.45, P < 0.001). PET/MRI radiation dose was significantly lower (53.35% ± 14.37% [P = 0.006]). In conclusion, PET/MRI is a feasible alternative to PET/CT in patients with NF1 when screening for the potential occurrence of MPNST. Reduction in radiation exposure approaches 50% compared to PET/CT.

Keywords

Neurofibromatosis type 1 - peripheral nerve sheath tumor - positron emission tomography/magnetic resonance


Publikationsverlauf

Artikel online veröffentlicht:
04. Juni 2024

© 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India